

CYduct Diagnostics, Inc. Signs LOI for Strategic Asset Acquisition

Published: Dec 02, 2020

WESTPORT, CT / December 02, 2020/ CYduct Diagnostics, Inc. (OTC PINK:CYDX) is pleased to announce it has signed a Letter of Intent to acquire all the assets of HHC PREFERRED LLC. ("HHC")

CYduct Diagnostics, an emerging innovator in the breast healthcare wellness segment of women's health, confirmed that it is in advanced talks to buy the assets of HHC including its HALO Nipple Aspirate Fluid ("NAF") acquisition system. The HALO technology is incorporated in a noninvasive device that utilizes patented technology to enable physicians to obtain samples of NAF in a clinical setting and these samples can then be used to screen for early identification of breast health risk. The HALO device extracts NAF from the mammary ducts, where nearly all breast health issues, including cancer, originate. NAF fluid essentially contains a mirror image of the microenvironment of the breast.

Dom L. Gatto, CEO of CYduct Diagnostics, commented: "Upon closing, expected before year-end, the acquisition of the HHC assets are predicted to add appreciably to CYduct Diagnostics' development of innovative approaches and improvements in the breast health market. We believe this action is one more step in a series of initiatives aimed at establishing CYduct Diagnostics' position within this dynamic market."

About CYduct Diagnostics, Inc.: CYduct Diagnostics Inc. is a medical device company pursuing innovations within the women's healthcare market, primarily breast healthcare and wellness. CYduct is focused on breast health and wellness through new testing methods that prioritize clinical integrity and patient privacy and convenience. The Company's history is rooted in providing quality medical products to healthcare market across the United States. For more than 30 years, from medical schools to hospitals, physicians have relied on the Company to develop medical devices, and procedural techniques for the screening, diagnosis, treatment and management of various diseases and medical conditions. Additional information on its line of products will be available on the Company's website at: www.cyductdx.com.

Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934 and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding the potential future plans and objectives of the Company, are forward-looking statements that involve significant risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. The inability to raise additional capital, and technical complications in research, product development and validation, among other things, could prevent the implementation of strategically significant plan(s) outlined above. The Company cautions that these forward-looking statements are further qualified by other factors including, but not limited to, those set forth in the Company's Annual Report filing and other filings with the OTC Markets Group (available at www.otcmarkets.com). The Company undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events, or otherwise.